Akeso, Inc. (HKG:9926)

Market Cap	63.68B
Revenue (ttm)	2.01B
Net Income (ttm)	-790.12M
Shares Out	897.56M
EPS (ttm)	-0.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,988,677
Average Volume	10,520,992
Open	68.00
Previous Close	68.45
Day's Range	67.40 - 72.15
52-Week Range	26.45 - 78.75
Beta	0.58
RSI	53.92
Earnings Date	Mar 14, 2025

About Akeso

Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovari...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 2,778
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9926

Financial Performance

Financial numbers in CNY